Protara Therapeutics, Inc. TARA 深 沪

Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.

05-15 23:36

美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价

今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元

05-15 10:49

JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.

05-15 02:19

Protara Therapeutics Q1 EPS $(0.31) Beats $(0.37) Estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.37) by 16.22 percent. This is a 6.9 percent decrease over losses of $(0.29) per share

05-13 20:07

美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元

今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元

04-30 19:24

Protara Therapeutics To Demonstrate Interim Data From Cohort A Of Its Current Phase 2 Open-Label ADVANCED-2 Study Of TARA-002 In Participants With BCG-Naïve Non-Muscle Invasive Bladder Cancer At American Urological Association 2026 Annual Meeting

Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data

04-28 04:10

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

04-27 20:05

Protara Therapeutics GAAP EPS of -$0.37

Protara Therapeutics press release (TARA): Q4 GAAP EPS of -$0.37. As of December 31, 2025, unrestricted cash and cash equivalents and marketable debt securities totaled $197.9 million, including proce...

03-11 03:11

Protara Q4 net loss widens on higher R&D spend

Protara Q4 net loss widens on higher R&D spend Overview Biotechnology firm's Q4 net loss was $17.3 mln, driven by increased R&D expenses Company completed $86 mln public offering, cash supports operations into 2028 Outlook Protara to provide regulatory update for TARA-002 in LMs in 1H 2026 Result Dr

03-10 20:07

Protara Therapeutics Q4 EPS $(0.37) Misses $(0.33) Estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 22.92 percent increase over losses of $(0.48) per share

03-10 20:03